<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="365">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 14, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00688623</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001CDE16</org_study_id>
    <nct_id>NCT00688623</nct_id>
  </id_info>
  <brief_title>RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe</brief_title>
  <acronym>RAMSETE/CDE16</acronym>
  <official_title>A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-endocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Germany: Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)</authority>
    <authority>Italy: Agenzia Italiana del Farmaco (AIFA)</authority>
    <authority>Netherlands: De Centrale Commissie Mensgebonden Onderzoek (CCMO)</authority>
    <authority>Poland: Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych</authority>
    <authority>Spain: Agencia Española del Medicamento</authority>
    <authority>Sweden: Läkemedelsverket</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the preliminary efficacy and safety of RAD001 as monotherapy  for first-line
      treatment of patients with metastatic papillary carcinoma of the kidney.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To evaluate the efficacy of RAD001 as monotherapy in patients with non syndromic neuro-endocrine tumours (NET). Efficacy is defined as the proportion of patients with complete (CR) or partial response (PR) according to RECIST criteria.</measure>
    <time_frame>At baseline, Every 12 weeks, at end of study treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the disease control rate (CR + PR + SD)</measure>
    <time_frame>Every 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the biochemical response rate based on the tumour marker CgA</measure>
    <time_frame>At baseline, Every 28 days or every 12 weeks, at end of study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate progression-free survival in this patient population</measure>
    <time_frame>done as required at statisticla analysis</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate overall survival in this patient population</measure>
    <time_frame>at date of last contact or at death</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To further characterize the safety profile of RAD001 (Incidence of AEs)</measure>
    <time_frame>Every 28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Carcinoma</condition>
  <condition>Neuroendocrine</condition>
  <condition>Non Functioning Neuroendocrine Tumors/NET</condition>
  <condition>Non Syndromic Neuroendocrine Tumors/NET</condition>
  <condition>Carcinoids</condition>
  <condition>Non Functioning</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. ≥ 18 years old

          2. Patients with advanced (unresectable or metastatic) biopsy proven non-syndromic
             neuro-endocrine carcinoma, low or intermediate grade

          3. Radiological documentation of disease progression within 12 months prior to study
             entry. If patients received anti-tumor therapy during the past 12 months, they must
             have radiological documentation of PD while on or after receiving the therapy

          4. Patients may have received previous treatments (chemotherapy, biotherapy,
             peptide-receptor radionuclide therapy); an overall maximum of 3 systemic treatment is
             allowed

          5. Patients with at least one measurable lesion

          6. Patients with an ECOG Performance Status 0-2

          7. Adequate bone marrow function

          8. Adequate liver function

          9. Adequate renal function

         10. Adequate lipid profile

        Exclusion criteria:

          1. Patients with poorly differentiated neuroendocrine carcinoma, high-grade
             neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell
             carcinoma

          2. Patients with carcinoid with hormone related symptoms (diarrhea ≥ 4 stools per day
             and/or flushes)

          3. Patients with Islet cell carcinomas or pancreatic NET

          4. Patients who received prior therapy with VEGF pathway inhibitor  within 4 weeks prior
             to study entry

          5. Patients who entered PRRT within 3 months prior to study entry

          6. Patients who received CT, biotherapy or radiotherapy within 4 weeks prior to study
             entry

          7. Patients who have previously received systemic mTOR inhibitors

          8. Patients with a known hypersensitivity to everolimus or other rapamycins or to its
             excipients

          9. Patients with uncontrolled central nervous system (CNS) metastases

         10. Patients receiving chronic systemic treatment with corticosteroids or another
             immunosuppressive agent

         11. Patients with a known history of HIV seropositivity

         12. Patients with autoimmune hepatitis

         13. Patients with an active, bleeding diathesis

         14. Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study

         15. Patients who have a history of another primary malignancy and off  treatment ≤ 3
             years, with the exception of non-melanoma skin cancer and carcinoma in situ of the
             uterine cervix

         16. Female patients who are pregnant or breast feeding, or adults of reproductive
             potential who are not using effective birth control methods

         17. Patients who are using other investigational agents or who had received
             investigational drugs ≤ 4 weeks prior to study treatment start

         18. Patients unwilling to or unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Berka</city>
        <zip>99438</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Viagrande</city>
        <state>CT</state>
        <zip>95029</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow - Scotland</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 9BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 20, 2015</lastchanged_date>
  <firstreceived_date>May 30, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuroendocrine tumors</keyword>
  <keyword>non-functioning neuroendocrine tumors carcinoids</keyword>
  <keyword>non-functioning carcinoids</keyword>
  <keyword>adults</keyword>
  <keyword>everolimus</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apudoma</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
